AZD5672 Absolute Bioavailability Study

Phase 1

Completed

Brief Summary: The purpose of the study is to estimate the absolute bioavailability at steady state of 2 doses of AZD5672 (50 mg and 150 mg administered orally once daily)

Recruitment & Eligibility

Inclusion Criteria

Provision of informed consent prior to any study specific procedures.
Females should not be of childbearing potential
Clinically normal physical and laboratory findings as judged by the investigator, including negative test results for drug-of-abuse, alcohol and cotinine at the Screening Visit and/or admission (Day -1) of each study period, and negative test results

Exclusion Criteria

Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate
Unsuitable venous access for intravenous studies
Participation in a clinical study involving an investigational product within 5 half-lives of active moieties of the last dose of investigational product or 3 months prior to first dosing (whichever is longer).

Arm && Interventions

Group	Intervention	Description
1	AZD5672	Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
2	AZD5672	2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose

Primary Outcome Measures

Name	Time	Method
PK variables	Frequent sampling occasions during study periods

Secondary Outcome Measures

Name	Time	Method
Safety variables (adverse events, blood pressure, pulse, safety lab)	During the whole treatment periods

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial